Without a doubt, electric vehicle charging station manufacturer ChargePoint (NYSE:CHPT) has disappointed many investors in 2023. CHPT stock has been a poor performer this year, and prudent traders should cut their losses and move on. If you’re not convinced of this, wait until you get the details of ChargePoint’s recent capital-raising efforts. Sure, ChargePoint’s management might
The recent strikes by Kaiser Permanente workers speak to greater structural issues that threaten weaker healthcare stocks in general. It’s clear that healthcare firms are increasingly under greater pressure to improve working conditions. That pressure magnifies issues for firms overall. Such firms can either acquiesce to union demands or face a heightened risk of further
Defense stocks are back in the spotlight amid rising global geopolitical tensions. The war in Russia and Ukraine was a testament to the rapidly evolving economic and political instability. Even as the economy faces many challenges, global aerospace and defense spending will continue to rise YOY. Several conflicts have emerged, including the recent Israel-Hamas war, leading
I’ve taken a generally bearish stance on Palantir Technologies (NYSE:PLTR) for quite some time now. That’s generally due to various fundamental concerns I have with the company, as well as questionable forward growth expectations.  However, putting all that aside, I thought I’d take a look at the bull case for Palantir. Let’s dive into the company’s
Sanjeri | E+ | Getty Images Company: Fortrea Holdings (FTRE) Business: Fortrea Holdings is a global contract research organization, or CRO, that provides clinical development and patient access solutions to the life sciences industry. CROs work with drug companies through all stages of the drug development process, from drug discovery and preclinical development to Phase